COMPOUND WITH CONFIDENCE: PCCA Membership, $795/month.

Pharmacy compounding's source for clinical information, regulatory updates, and opportunities

THE PCCA BLOG

rss

Stay current on PCCA news and events, market trends, and all things compounding!

202305_BB_GSM Common Sympton of Menopause.png

Genitourinary syndrome of menopause (GSM), also known as vulvovaginal atrophy, is common among menopausal women. Learn more about GSM, relevant hormones and the importance of choosing the right base for compounding preparations.

202209_ Blog_WomensHealth_823x4622 (1).jpg

Women’s Health

Wellness Works Manager Stephanie Allen reviews nutritional supplements that may help women thrive.

Topical_Compounded_Treatment_Options_for_Painful_Vaginal_and_Vulvar_Conditions.jpg

Tricia Heitman of PCCA's Clinical Services Team discusses compounded treatment options for women suffering from atropic vaginitis, vluvar lichen sclerosis, desquamative inflammatory vaginitis, vaginismus, high-tone pelvic floor dysfunction and vulvodynia.

The_Science_behind_Ellage_Anhydrous_Vaginal_Base.jpg

Maria Carvalho, Manager of PCCA Science, provides an in-depth look at the science behind Ellage, the first ever anhydrous compounding base developed specifically for vaginal delivery of medications.

4_Reasons_to_Use_Ellage_Anhydrous_Vaginal_Base_in_Your_Compounding_Pharmacy.jpg

With the debut of Ellage at International Seminar 2020, PCCA has introduced a revolutionary anhydrous vaginal base. Here are just a few of the exciting reasons why Ellage should be your pharmacy's go-to base when it comes to vaginal applications.

PCOS_More_than_Insulin_Resistance.jpg

Sara Hover of PCCA's Clinical Services discusses medical treatment and management options for pharmacists helping patients whose health is challenged by polycystic ovary syndrome (PCOS).

2Oral_vs_Topical_Estrogen_What_the_Literature_Is_Showing_about_Health_Risk_Part_Two.png

In the first part of this article, Pamela, Nat, and Sara shined a light on new health risk information compounders should consider when providing bioidentical hormone replacement therapy. In this second part of the article, they dive deeper into the BHRT conversation, discussing compounded topical estrogen as an option.

Oral_vs_Topical_Estrogen_What_the_Literature_Is_Showing_about_Health_Risk_Part_One.png

Compounded bioidentical hormone replacement therapy (BHRT) is an important treatment option for women around the world. Colleagues and patients alike come to PCCA experts Pamela Smith, Nat Jones and Sara Hover for guidance. In this article, our three experts cover this all-too-important topic in the HRT conversation, on what current literature says about the usage of oral vs. topical estrogen discussion.

A_New_Anhydrous_Base_for_Female_Hormone_Delivery.png

PCCA launches an exciting new base at their 2019 International Seminar. Click here to learn all about it.

201904_ThePCCABlog_VersaBase_1768x500.png

Compounding pharmacies have been using PCCA's VersaBase Cream for years. Today, we'd like to talk to you about VersaBase's incredible ability to assist in women's Hormone Replacement Therapy.